AlphAIAlphAI — Financial news for AI agents
tradingview.comNOV 21 min read$TEM

Tempus AI 3Q 2026: Revenue $411.5M, Net loss $14.9M — 10-Q Summary

Tempus AI reported Q3 2026 revenue of $411.5M, up 23% YoY, and a net loss of $14.9M, improved from $80M a year earlier. Diagnostics and Data and applications revenue grew, with adjusted EBITDA at $25.6M. The company expanded its oncology and hereditary testing and closed the acquisition of Center Health.

Original reporting
tradingview.com
Published Nov 2, 2026, 12:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 2, 2026, 12:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Tempus AI 3Q 2026: Revenue $411.5M, Net loss $14.9M — 10-Q Summary — source image
Source · tradingview.com
Decision brief

The 30-second read

$TEMBullishMed
01

Why it matters

The earnings beat and loss reduction could trigger short‑term buying, especially from investors focused on AI‑enabled health tech.

02

Market read

First‑report earnings for a mid‑cap AI health‑tech firm; material for traders watching the sector.

03

What to watch

Potential integration risk from recent Center Health acquisition and reliance on large pharma collaborations.

Relevance 7/10Novelty 7/10Timing: post-market today

Background

Tempus AI is a data‑driven precision medicine company that provides diagnostic testing and analytics services.

Company-level read

Ticker impact

$TEMBullishHigh confidence
Context

Tempus AI reported Q3 2026 revenue of $411.5M and narrowed net loss to $14.9M, a fresh earnings disclosure.

Expected impact

likely modest upside as the market prices in the narrowed loss and revenue beat.

Evidence & confidence

Revenue up 23% YoY and loss sharply reduced; investors typically reward such earnings improvements.

Market effects

Sector

Positive signal for the diagnostics and health‑data sector, may lift peers.

Regional

U.S. biotech/health‑tech segment could see modest buying pressure.

Global

Limited to investors tracking AI‑enabled healthcare companies.

Counterpoint

What could challenge this read

Revenue growth may not be sustainable; high valuation could limit upside.

Key entities

  • Company
    Tempus AI, Inc.

    Provider of AI‑driven diagnostics and data analytics.

  • Partner
    AstraZeneca

    Collaborates with Tempus on an oncology foundation model.

Read at source← All news

StoryTempus AI posts record Q3 revenue, first adjusted profit and raises full‑year outlook

Also covered by

6 outlets

Related articles

NOV 3
$TEMMed

Tempus AI Inc (TEM) Q3 2026 Earnings Call Highlights: Revenue Jumps 23%

Tempus AI Inc (TEM) reported Q3 2026 revenue of $411M, up 23%. CEO Lefkofsky expects sustainable 25%+ growth, with oncology and data segments driving performance. The company anticipates mid-2027 breakeven for Personalis' MRD test and predicts strong market share in MRD. Tempus also highlighted long-term data business commitments and AI-driven customer stickiness.

finance.yahoo.com2 min
NOV 2
$TEMMedAI 8/10

Tempus AI (TEM): Oncology Volume Surge and Data Licensing Bookings Signal a Profitable Inflection

Tempus AI (TEM) reported Q3 2026 revenue of $411.5M, up 23% YoY, with adjusted EBITDA of $25.6M. Oncology revenue grew 28% to $172.6M, while Data and Applications revenue increased 33% to $108.1M. The company raised full-year revenue guidance to $1.60B-$1.605B and expects near-term catalysts from reimbursement improvements and the pending $1.7B Personalis acquisition.

news.alphastreet.com7 min